Advisors Capital Management LLC Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Key Points

• Advisors Capital Management purchased 66,082 shares of Thermo Fisher Scientific in the second quarter, valued at approximately $33.1 million. Institutional investors collectively own 89.23% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $619.41; recent targets range as high as $650.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, with revenue up 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share, while insiders have sold shares worth approximately $37.7 million over the past 90 days.

Advisors Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 66,082 shares of the medical research company's stock, valued at approximately $33,131,000.

A number of other large investors have also modified their holdings of the company. J. Stern & Co. LLP boosted its position in shares of Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the period. BlackRock Inc. acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $15,501,867,000. Norges Bank bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $3,072,744,000. Bank of New York Mellon Corp acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth $1,974,561,000. Finally, Auto Owners Insurance Co grew its stake in shares of Thermo Fisher Scientific by 57,845.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock worth $1,406,844,000 after purchasing an additional 2,423,706 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analyst Weigh In

TMO has been the subject of several research analyst reports. HSBC downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective for the company. Barclays boosted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Finally, Morgan Stanley upped their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $628.24 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm's 50 day moving average is $539.33 and its 200-day moving average is $508.86. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The stock has a market capitalization of $232.29 billion, a P/E ratio of 33.79, a P/E/G ratio of 2.50 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm's revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at $71,191,194.75. The trade was a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 63,493 shares of company stock valued at $37,657,681 over the last 90 days. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source